Gene therapy companies have an ethical obligation to develop expanded access policies
- PMID: 33714373
- PMCID: PMC8058481
- DOI: 10.1016/j.ymthe.2021.03.008
Gene therapy companies have an ethical obligation to develop expanded access policies
Conflict of interest statement
L.K., A.L.C., A.M., P.F., and A.B.-H. are members of the Working Group on Pediatric Gene Therapy and Medical Ethics (PGTME) at the Division of Medical Ethics at NYU Grossman School of Medicine. PGTME is funded by a gift from Parent Project Muscular Dystrophy (PPMD), of which Pat Furlong is founder and president.
Comment in
-
Financial considerations in expanded access policy for gene therapies: A tough nut to crack?Mol Ther. 2021 Jun 2;29(6):1936. doi: 10.1016/j.ymthe.2021.04.030. Epub 2021 May 8. Mol Ther. 2021. PMID: 33964226 Free PMC article. No abstract available.
References
-
- Chapman C.R., Moch K.I., McFadyen A., Kearns L., Watson T., Furlong P., Bateman-House A. What compassionate use means for gene therapies. Nat. Biotechnol. 2019;37:352–355. - PubMed
-
- Darrow J.J., Sarpatwari A., Avorn J., Kesselheim A.S. Practical, legal, and ethical issues in expanded access to investigational drugs. N. Engl. J. Med. 2015;372:279–286. - PubMed
-
- Usdin S. 2018. FDA to facilitate access to unapproved drugs. BioCentury, December 14, 2018.https://www.biocentury.com/article/299854/how-fda-plans-to-help-patients...
-
- 114th Congress . 2016. 21st Century Cures Act: Public Law 114–255—Dec. 13, 2016.https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf
-
- U.S. Food and Drug Administration . 2020. Expanded access.https://www.fda.gov/news-events/public-health-focus/expanded-access
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
